Man Group plc Buys New Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Man Group plc acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 21,825 shares of the company's stock, valued at approximately $810,000.

Other large investors have also modified their holdings of the company. Pacer Advisors Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after acquiring an additional 1,347,775 shares during the last quarter. D.A. Davidson & CO. purchased a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter valued at $417,000. Barclays PLC boosted its stake in shares of Amphastar Pharmaceuticals by 53.3% during the third quarter. Barclays PLC now owns 74,456 shares of the company's stock valued at $3,613,000 after purchasing an additional 25,878 shares during the period. Raymond James Financial Inc. purchased a new position in Amphastar Pharmaceuticals in the 4th quarter worth about $3,450,000. Finally, Polaris Capital Management LLC purchased a new position in Amphastar Pharmaceuticals in the 4th quarter worth about $910,000. Hedge funds and other institutional investors own 65.09% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on AMPH shares. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 price target (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Wells Fargo & Company reduced their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Finally, Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $32.33.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. The trade was a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 5,231 shares of company stock worth $142,752 in the last three months. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Stock Up 0.2%

Shares of AMPH traded up $0.05 during mid-day trading on Friday, hitting $25.69. The company's stock had a trading volume of 57,102 shares, compared to its average volume of 481,299. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The company's 50-day moving average is $24.97 and its 200-day moving average is $32.39. Amphastar Pharmaceuticals, Inc. has a 52-week low of $22.64 and a 52-week high of $53.96. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of 8.56, a PEG ratio of 2.19 and a beta of 0.78.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.